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The synthesis of a drug delivery platform based on graphene was achieved through a step-by-
step strategy of selective amine deprotection and functionalization. The multifunctional 
graphene platform, functionalized with indocyanine green, folic acid and doxorubicin showed 
an enhanced anticancer activity. The remarkable targeting capacity for cancer cells in 
combination with the synergistic effect of drug release and photothermal properties prove the 
great advantage of a combined chemo- and phototherapy based on graphene against cancer, 




In the last decades, the interest on the applications of nanomaterials in nanomedicine has raised 
up very fast. New drug delivery platforms, based on different types of nanoparticles, carbon 
nanotubes, graphene, and other materials, have been developed.[1,2] The large variety of 
reactions offered by the chemistry of these materials and their intrinsic properties permit the 
combination features, like specific cell targeting, controlled drug release, photothermal and 
photodynamic therapies, and imaging.[3–5] Drugs, as doxorubicin or paclitaxel, present great 
anticancer activity but low water solubility that reduce their therapeutic efficacy and suffers of 
undesired side effects.[6] A great advantage of nanomaterials as drug delivery systems consists 
on their ability to complex high quantity of hydrophobic drugs on their surface, improving the 
uptake and release of the drug in cancer cells, and reducing the non-selectivity of the free 
drugs.[2,7] Moreover, fundamental properties to consider in the development of new systems are 
their biocompatibility, the amount of drug loading, the interactions with the biological 
environment and the biodistribution into the body after administration.[8] Within the wide range 
of nanomaterials, graphene has been found to have a good biocompatibility and 
biodegradability, leading to explore this form of carbon as drug delivery carrier.[9,10] Moreover, 
its high surface/mass ratio (theoretical: 2630 m2/g) allows a high drug loading, by absorbing 
organic molecules through π-π stacking or hydrophobic interaction. Thanks to an easy 
functionalization and to its good water dispersibility, graphene oxide (GO), the oxidized form 
of graphene, has been largely studied as drug carrier. Indeed, following the pioneer work of Dai 
and co-workers,[11] many other groups have investigated the applications of GO for drug 
delivery.[1] GO and its derivatives, thanks to their easy process of functionalization, have been 
widely employed to produce drug delivery platform.[12] On the other hand, this easy 
functionalization can lead to a non-selective site reaction and, eventually, side reactions with 
amines present in the organism. Moreover, the highly defective GO surface is able to form 
radical species and the material is not stable in reducing conditions, with the risk to modification 
of the functional groups, the stability and the chemical properties. Graphene is presenting a 
higher chemical stability respect to GO to reductive conditions and fewer interactions with cells 
membrane due to functional groups on its surface. However, to the best of our knowledge no 
published studies have reported the use of pristine graphene as drug delivery carrier, despite its 
great potential in nanomedicine.[13] Following the past studies performed by our group on the 
multifunctionalization of carbon nanotubes,[3] we have designed and synthetized a covalent 
multifunctional graphene platform (mfG), suitable for cancer therapy applications. Our study 
has focused on targeting, tracking, delivery and photothermal activity of mfG on cancer cells. 
We selected indocyanine green (ICG) as fluorophore to follow the uptake and to track the 
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material inside the cells. Folic acid (FA) was covalently bound through a PEG linked to 
graphene, to specifically target the cancer cells, and doxorubicin (Dox) was used as anticancer 
drug. We investigated the in vitro properties of this multifunctional conjugate using HeLa cells, 
showing very promising results and low toxicity, as confirmed by in vivo biocompatibility tests 
performed on mice.  
The platform designed for our study is characterized by the presence of three functionalities, 
ICG as fluorophore, FA as targeting agent and DOX as therapeutic molecule. The starting 
material to prepare this platform corresponds to a multifunctional graphene recently described 
(Figure S1).[14] mfG, obtained through one-pot covalent multifunctionalization of KC8 with 
diazonium salts, is bearing three orthogonally protected benzylamine derivatives that allow a 
specific strategy of step-by-step amine deprotection and functionalization. Following the 
sequential removal of each protecting group, the order of introduction of the new functionalities 
is crucial for achieving the final desired conjugate. The chemical stability of each functional 
group under the deprotection conditions of each amine was initially investigated, in order to 
establish the synthetic route. The optimized strategy, shown in Scheme 1 (see SI for complete 
synthetic details), started from phthalimide (Pht) deprotection (1) followed by the amidation 
with 4-pentynoic acid (2), introducing an alkyne as first functional group. The selective 
reactivity of the alkyne with azides and its stability to tertbutyloxycarbonyl (Boc) and 
benzyloxycarbonyl (Cbz) deprotection conditions make this functional group an orthogonal 
reactive site respect to the other protected amines. The common characterizations techniques 
for organic reactions, such as TLC and 1H-NMR are not applicable to follow the 
functionalization of graphene nanomaterials, making the characterization of each reaction step 
difficult and sometime uncertain. To understand the evolution of the reaction, we exploited the 
presence of primary amines, applying the colorimetric Kaiser test, to evaluate the amount of 
free amines before and after the reactions[15] The quantity of primary amines after step (1) 
resulted 55 µmol/g, and decreased to 14  µmol/g after the amidation (2), corresponding to a 
final loading of 4-pentynoic acid of ~41 µmol/g (75% yield). Through this procedure we were 





Scheme 1: Schematic representation of the synthetic routes followed to the functionalize mfG to 
obtain mfG/PEG-FA/ICG/Dox. 
After the introduction of the alkyne moiety, Boc protection was removed (3) (~ 33 µmol/g) and 
the amine was functionalized with a PEG chain protected with a Boc at the amino group and 
activated as N-hydroxysuccinimide (NHS) at the carboxylic function (NHS-PEG-Boc) (MW, 
3000 Da) (4) (zero µmol/g of free amines was measured, quantitative yield). The PEG chain 
plays two important roles: to increase water dispersibility and the biocompatibility of graphene 
and to act as a spacer for the linking of FA to the conjugate. After Boc deprotection of the PEG 
chain (5) (~30 µmol/g), the amines were functionalized with a preformed NHS-FA derivative 
(6) (zero free amines were measured after the coupling, quantitative yield). FA stability to Cbz 
deprotection was already demonstrated by Ménard-Moyon et al. on carbon nanotubes allowing 
the next steps of chemical modification.[3] The removal of Cbz group under strong acid 
conditions (7) liberated the last amines (~30 µmol/g free amine), employed for the final step of 
mfG functionalization. Before this reaction, indocyanine green was introduced by click 
chemistry (8). In this case the reaction was monitored by fluorescence measurement of 
functionalized graphene in NMP. Due to partial quenching of the fluorescence by graphene,[16] 
it is not possible to quantitative evaluate the loading of ICG through direct spectroscopic 
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comparison. To prove that the observed fluorescence was due to the covalent grafting of the 
fluorophore and not to ICG physisorbed onto the surface, a control reaction was performed in 
absence of the click copper catalyst. No fluorescence was measured on this control reaction 
while the conjugate obtained from step (8) had a maximum of emission at 818 nm, confirming 
the covalent reaction (Figure 1a). 
 
Figure 1: a) Fluorescence of mfG/PEG-FA/ICG (red line) and control mfG/PEG-FA reaction (black 
line). Conc. 0.1 mg/mL of graphene conjugate in NMP. λex: 750 nm, λem: 780-900 nm; b) Histogram of 
the lateral size distribution of the mfG/PEG-FA/ICG/Dox 
As last step, doxorubicin was introduced onto mfG through an imine bond. The bond was 
formed between the last free amines on mfG and the ketone of Dox to obtain mfG/PEG-
FA/ICG/Dox (mfG-Dox). The characteristics of imine bond is its reversibility in acidic 
condition, at pH < ~5.5.[17] Indeed, the imine bond can be selectively cleaved in tumour 
microenvironment, where pH is more acidic than healthy tissues, thanks to an increased 
therapeutic approach given by the presence of folic acid on graphene. Because of an additional 
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amine on Dox structure and its low stability to temperature, the Kaiser test could not be applied 
to evaluate the loading of drug onto graphene. We evaluated the amount of Dox grafted on mfG 
through HPLC analysis by measuring the difference between the initial amount of drug and the 
quantity of free Dox in solution after the reaction. mfG were separated from the reaction mixture 
and steps of dispersion of the material in PBS, centrifugation and removal of the supernatant 
containing free Dox were repeated until no presence of drug was found in the solution. The 
total amount of free Dox was measured by HPLC. The quantity of Dox linked to graphene 
corresponded to ~ 60 µg/g (~0.10 µmol/g). We hypothesized that the low reaction yield was 
due to a difficult encounter between the drug and the free amines, due to steric hindrance caused 
by PEG chain and the other functionalities on the surface of graphene. 
The dimensions of the sheets could affect the cells uptake and cytotoxicity. As reported by 
several studies, sheets with lateral size distribution above 1 µm present higher cytotoxicity 
respect to smaller graphene and graphene oxide sheets.[18–20] Therefore, we evaluate the average 
lateral size of the particles by statistical analysis using transmission electron microscopy (TEM) 
images (Figure S2), obtaining a value of ~794 nm, with the presence of few particles smaller 
than 200 nm or bigger than 1.5 µm (Figure 1b). 
Following the synthesis and characterization of the conjugate, we proceed to evaluate its 
therapeutic potential on cancer cells. In vitro anticancer activity of mfG nanoconjugate to serve 
as a drug delivery carrier was evaluated using the water-soluble tetrazolium (WST)-based 
assay. After 48 h of incubation at increasing doses (5 to 76 µg/mL), a slight cell mortality was 
observed for HeLa cells incubated with mfG-Dox and with the control mfG (corresponding to 
the functional material without Dox).  (Figure S3). The observed cell viability of mfG-Dox and 
mfG was comparable, with a slight decrease to ~95 % in concentration higher than 50 µg/mL. 
We attributed the failure of the treatment to two main factors: 1) a fast reaggregation of the 
nanosheets due to low water dispersibility, hindering a high cell uptake, and to a low amount 
of Dox linked to graphene. To improve the water solubility, we decide to employ bovine serum 
albumin (BSA) as surfactant. This protein is well known to be a biocompatible dispersant, able 
to maintain graphene well suspended in water.[21] To increase the quantity of Dox, we decided 
to exploit the hydrophobicity of graphene surface. Doxorubicin can be adsorbed onto graphene 
mainly by π-π stacking interactions, leading to a combined strategy, based on covalently linked 
and physically adsorbed drug onto graphene surface. To achieve our goal, we sonicated the 
prepared mfG/PEG-FA/ICG/Dox in a BSA and Dox solution (1 mg/mL BSA, ratio mfG/Dox 
1:0.25 w/w. See SI for the method). The final material results to be stable in water and in cell 
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culture media for more than 24 h (mfG/PEG-FA/ICG/Dox at 1 mg/mL conc.). The total quantity 
of Dox was evaluated by UV-Vis spectroscopy as difference between the initial amount of Dox 
and the free drug in solution after absorption, giving a value of ~ 101 µg/mg. With the new 
conjugate in hand, we first evaluated the drug release efficiency in neutral and acidic conditions 
(pH 7.4 and 5.5, respectively), showing a higher drug release at pH 5.5 after 24 h (36.7%) 
compared to neutral pH conditions (14.5%) (Figure S4). We then evaluated again the in vitro 
performance. After 24 h of incubation, a small decrease in the viability of the cells was 
observed, with a slight difference between the control material and mfG/PEG-FA/ICG/Dox 
(Figure 2a). However, after 48 h treatment, Dox conjugated mfG showed a dose-dependent 
cytotoxicity to HeLa cells, whereas BSA (vehicle control) and mfG/PEG-FA/ICG (nanocarrier) 
did not induce any significant difference in cell viability (Figure 2b). We would like to evidence 
that mfG/PEG-FA/ICG/Dox showed greater toxicity to HeLa cells at all doses as compared to 
MRC5 normal fibroblasts (Figure S5). As folate receptor (FR) is overexpressed in cancer cells 
in comparison to normal cells,[22] we hypothesized that such selective anticancer activity was 
mediated by folate receptor-directed targeting effect. To test this, we subjected HeLa cells to 
folate starvation and performed an antagonist experiment by pre-incubating these cells with or 
without an excess of folic acid (10 µM). As shown in Figure 2c, the cancer-killing activity of 
mfG/PEG-FA/ICG/Dox was retarded by blocking folate receptor. This is likely because the 
excess of folic acid occupied folate receptors and interfered with the internalization of mfG 
conjugates by the cells. Taken together, these results demonstrated that Dox-complexed and 
folic acid-functionalized mfG graphene nanosheets could be used as an effective nanocarrier 




Figure 2: Cells viability experiment on HeLa cells. In x-axis mfG corresponds to concentration of 
incubated graphene material, while Dox is the corresponding quantity of drug present on the material. 
a) Cell viability assay of HeLa cells treated with BSA, mfG/PEG-FA/ICG and mfG/PEG-FA/ICG/Dox 
for 24 h. Data are expressed as means ± s.e.m. (n=4), *p < 0.05, **p < 0.01,***p < 0.001(Student’s t 
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test to 0 µg/mL); b) Cell viability assay of HeLa cells treated with BSA, mfG/PEG-FA/ICG and 
mfG/PEG-FA/ICG/Dox for 48 h. Data are expressed as means ± s.e.m. (n=4), ***p < 0.001(Student’s t 
test to 0 µg/mL); c) Viability of HeLa cells treated with mfG/PEG-FA/ICG/Dox for 48 h with/without 
pretreatment of free folic acid (FA; 10 % Data are expressed as means ± s.e.m. (n=4), ***p < 0.001 
(Student’s t test comparisons with the equivalent concentration of FA pretreated counterpart). 
 
To visualize the cellular uptake behavior of mfG nanoconjugates, HeLa cells were incubated 
with the ICG-labelled mfG for 4 h and they were subjected to live cell imaging after washing 
with PBS. In line with fluorescence spectra results (Figure 1), the fluorescence signals of 
mfG/PEG-FA/ICG were clearly observed using 800 nm filter setup (Figure S6a), confirming 
the successful incorporation of ICG fluorophore onto mfG. The fluorescent image merged with 
differential interference contrast images (DIC) revealed that mfG nanoconjugates were 
accumulated into the cytoplasm, although ICG moieties were partly quenched, as showed by 
the presence of black aggregates (Figure S6b). To finally confirm the targeting activity and drug 
release, we observed the release of doxorubicin using confocal fluorescence microscopy. We 
found that in the complete cell culture medium we can appreciate a release of Dox inside HeLa 
cells after 4 h from incubation (Figure S7 and S8). However, a pretreatment with enriched folic 
acid media (to saturate FA receptors) significantly decreased Dox internalization. 
The synergistic effect following the heating of nanomaterials under near-infrared irradiation 
(NIR) in combination with the enhancing of the activity of Dox at high temperature has been 
shown to increase the effectiveness of anti-cancer therapy.[23,24] To explore the combination of 
these two effects exploiting photothermal properties of graphene, we investigated the cell 
viability of HeLa cells incubated with our drug delivery carrier. HeLa cells were incubated with 
BSA, ICG and mfG/PEG-FA/ICG/Dox for 4 h and then have been irradiated for 10 min using 
a 785 nm fiber-coupled continuous-wave NIR laser at 1 W (ca. 8 W/cm2). The viability of the 
cells was measured at 0, 24 or 48 h post-irradiation. As shown in Figure 4, laser irradiation did 
not alter the viability of the cells treated with BSA and ICG. Interestingly, photoinduced 
mfG/PEG-FA/ICG/Dox shows no effect on viability immediately after laser irradiation. This 
behavior could be attributed to the non-sufficient increase in the temperature (~ 15 °C DT from 
room temperature, Figure S9) due to the low concentration of graphene employed. However, a 
significant reduction of viability was observed after 24 h post-irradiation (Figure 3). This 
behavior can likely be attributed to the synergistic effect of the heat induced by the laser 
irradiation and a fast Dox release from mfG by the intracellular acidic environment and laser-
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driven temperature increase, exerting an efficient cell killing effect within the following 24 h 
(Figure S10).[24] Despite this first decrease in cells viability, the difference after 48 h post-
irradiation is less evident than what observed after 24 h of incubation (Figure S11a). This is 
because the cell viability of the different treated cells is converging to the already observed cell 
viability after 48 h of incubation (Figure 2b and Figure S11b), with a slight decrease of the 
value for the irradiated cells. Comparing to the similar nanoconjugate based on graphene oxide, 
laser-irradiated mfG/PEG-FA/ICG/Dox exhibits a better anticancer performance.[23] The 
observed results are indicating that mfG/PEG-FA/ICG/Dox has potential to be used for 
multimodal synergistic therapy (chemo- and phototherapy) decreasing the activation of the 
therapy and increasing its effectiveness in cancer-killing activity. 
 
 
Figure 3: Cell viability of HeLa cells treated with BSA (20 µg/mL), ICG (0.9 µg/mL) and mfG/PEG-
FA/ICG/Dox (20 µg/mL) with/without 785 nm laser irradiation for 10 min. The cell viability was tested 
at 0 and 24 h after irradiation. The concentrations of BSA and ICG were carefully adjusted to the 
equivalent amounts loading on the mfG nanoconjugates. Data are presented as mean ± s.d. (n = 3), ∗∗∗p 
< 0.001 (Student’s t test). 
To assess the biosafety of mfG nanosheets without modifications (Figure S1), we dispersed the 
material in BSA solution (1 mg/mL) and incubated HeLa cells with a wide range of 
concentrations of mfG and evaluated cell viability at 24 and 48 h post treatment. The resulted 
revealed that mfG did not affect cell viability even up to the concentration of ca. 150 µg/mL, 
indicating that it is safe for biomedical use (Figure S12).  
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Finally, in vivo toxicity evaluation was examined by measuring key blood parameters. Due to 
low water dispersibility of mfG (the starting material used for the synthesis of our conjugate), 
mice were intravenously injected 100 µL of the starting mfG (at 0.5 mg/mL, 2.5 mg·kg-1) and 
PBS. Blood test was performed at day 1 and day 7 post injection. The hematological and 
biochemical parameters did not differ between the groups of mfG and PBS (Table S1 and S2), 
demonstrating the lack of acute inflammatory response and underscoring the biosafety of mfG. 
To conclude, in this study we designed and synthesized a multifunctional graphene-based 
platform for cancer therapy applications. We demonstrated the combined chemo- and 
photothermal properties of the multifunctional graphene as drug delivery carrier, based on the 
targeting ability of folic acid for HeLa cells, the low in vitro and in vivo toxicity of the starting 
material and the good cancer killing activity shown by the composite functionalized with 
doxorubicin. The internalization was confirmed by live microscopy exploiting ICG as 
fluorophore moiety. As ICG has been also demonstrated to generate reactive oxygen species 
under irradiation, it could be explored as photodynamic agent.[25,26] The advantages of using 
graphene as drug carrier were demonstrated in virtue of the synergistic effect of the photo- and 
chemotherapy after NIR irradiation, making graphene-based material a promising platform for 
combined cancer therapy applications. 
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A multifunctional drug delivery platform based on graphene, functionalized with indocyanine 
green, folic acid and doxorubicin was designed and prepared, leading to an efficient combined 
chemo- and photothermal effect in cancer therapy. 
